HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

Abstract Background HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted therapies. The concept of HER2-low BC (IHC score...

Full description

Bibliographic Details
Main Authors: François Cherifi, Angélique Da Silva, Alison Johnson, Cécile Blanc-Fournier, Olivia Abramovici, Antonin Broyelle, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Clémence Boscher, Coraline Dubot-Poitelon, Pauline Rottier, Justine Lequesne, George Emile
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Cancer
Subjects:
Antibody–drug conjugates
HER2-low
Breast cancer
Trastuzumab–deruxtecan
Neoadjuvant treatment
Lymphocytes
Online Access:https://doi.org/10.1186/s12885-022-10163-9

Internet

https://doi.org/10.1186/s12885-022-10163-9

Similar Items